Beam Therapeutics Inc. Proceeds from Stock Plans
Beam Therapeutics Inc. (BEAM) reported Proceeds from Stock Plans of $1.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-04
- Beam Therapeutics Inc. proceeds from stock plans for the quarter ending 2026-06-30 was $0.00.
- Beam Therapeutics Inc. proceeds from stock plans for the quarter ending 2026-03-31 was $1.51M, a 0.60% increase year-over-year.
- Beam Therapeutics Inc. proceeds from stock plans for the quarter ending 2025-12-31 was $0.00.
- Beam Therapeutics Inc. proceeds from stock plans for the quarter ending 2025-09-30 was $1.26M, a 3.19% increase year-over-year.
- Beam Therapeutics Inc. proceeds from stock plans for fiscal 2025 was $2.76M, a 5.46% increase from fiscal 2024.
- Beam Therapeutics Inc. proceeds from stock plans for fiscal 2024 was $2.62M, a 13.56% decline from fiscal 2023.
- Beam Therapeutics Inc. proceeds from stock plans for fiscal 2023 was $3.03M, a 1.40% decline from fiscal 2022.
- Beam Therapeutics Inc. proceeds from stock plans for fiscal 2022 was $3.08M.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.51M 10-Q · filed 2026-08-04 | $1.51M derived: sum of 3 quarters · filed 2026-08-04 | $2.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-07 | $1.51M derived: sum of 2 quarters · filed 2026-05-07 | $2.77M derived: sum of 3 quarters · filed 2026-05-07 | $2.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.26M derived: sum of 2 quarters · filed 2026-02-24 | $1.26M derived: sum of 3 quarters · filed 2026-08-04 | $2.76M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.26M derived: sum of 2 quarters · filed 2026-08-04 | $2.76M 10-Q · filed 2025-11-04 | $2.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.50M 10-Q · filed 2026-08-04 | $1.50M derived: sum of 3 quarters · filed 2026-08-04 | $2.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-07 | $1.50M derived: sum of 2 quarters · filed 2026-05-07 | $2.72M derived: sum of 3 quarters · filed 2026-05-07 | $2.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.22M derived: sum of 2 quarters · filed 2026-02-24 | $1.22M derived: sum of 3 quarters · filed 2026-02-24 | $2.62M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.22M derived: sum of 2 quarters · filed 2025-11-04 | $2.62M 10-Q · filed 2025-11-04 | $2.62M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.40M 10-Q · filed 2025-08-05 | $1.40M derived: sum of 3 quarters · filed 2026-02-24 | $2.72M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-06 | $1.40M derived: sum of 2 quarters · filed 2026-02-24 | $2.72M derived: sum of 3 quarters · filed 2026-02-24 | $2.72M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.32M derived: sum of 2 quarters · filed 2026-02-24 | $1.32M derived: sum of 3 quarters · filed 2026-02-24 | $3.03M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.32M derived: sum of 2 quarters · filed 2024-11-05 | $3.03M 10-Q · filed 2024-11-05 | $3.03M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.71M 10-Q · filed 2024-08-06 | $1.71M derived: sum of 3 quarters · filed 2025-02-25 | $3.37M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.71M 10-Q · filed 2024-05-07 | $1.71M derived: sum of 2 quarters · filed 2025-02-25 | $3.37M derived: sum of 3 quarters · filed 2025-02-25 | $3.37M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.66M derived: sum of 2 quarters · filed 2025-02-25 | $1.66M derived: sum of 3 quarters · filed 2025-02-25 | $3.08M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.66M derived: sum of 2 quarters · filed 2023-11-08 | $3.08M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.41M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.41M 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |